title: [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
abstract: Ocular adverse effects of interferon are described during the treatment of malignant diseases and chronic viral hepatitis with interferon alpha. At this time, there is no report of these effects during multiple sclerosis treatment with interferon beta-1b. The authors report a bilateral retinopathy during this treatment. The production of neutralizing antibodies during interferon beta-1b treatment leads to a decrease in diminution of therapeutic efficacy. When treatment failure occurs, neutralizing antibodies are to be tested.
authors.affiliation: CHR N.D. de Bonsecours, 1 pl Ph de Vigneulles, 57038 Metz cedex 1.
authors.forename: S
authors.initials: S
authors.lastname: Sommer
authors.forename: J C
authors.initials: JC
authors.lastname: Sablon
authors.forename: M
authors.initials: M
authors.lastname: Zaoui
authors.forename: P
authors.initials: P
authors.lastname: Rozot
authors.forename: A
authors.initials: A
authors.lastname: Hosni
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000328:Adult; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009887:Ophthalmoscopy; D012164:Retinal Diseases / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D014792:Visual Acuity
chemical_list: D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a